Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers
A Phase I, Randomized, Double-blind, Placebo- and Active-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of DWP16001 Following Oral Administration in Healthy Male Volunteers
Sponsor: Daewoong Pharmaceutical Co. LTD.
Listed as NCT03364985, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Daewoong Pharmaceutical Co. LTD., it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Daewoong Pharmaceutical Co. LTD.
For direct contact, visit the study record on ClinicalTrials.gov .